JP2014503565A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503565A5
JP2014503565A5 JP2013550826A JP2013550826A JP2014503565A5 JP 2014503565 A5 JP2014503565 A5 JP 2014503565A5 JP 2013550826 A JP2013550826 A JP 2013550826A JP 2013550826 A JP2013550826 A JP 2013550826A JP 2014503565 A5 JP2014503565 A5 JP 2014503565A5
Authority
JP
Japan
Prior art keywords
weight
chain fatty
long chain
formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013550826A
Other languages
English (en)
Japanese (ja)
Other versions
JP6012632B2 (ja
JP2014503565A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/050695 external-priority patent/WO2012101016A1/en
Publication of JP2014503565A publication Critical patent/JP2014503565A/ja
Publication of JP2014503565A5 publication Critical patent/JP2014503565A5/ja
Application granted granted Critical
Publication of JP6012632B2 publication Critical patent/JP6012632B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013550826A 2011-01-26 2012-01-18 テストステロン製剤 Expired - Fee Related JP6012632B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161436207P 2011-01-26 2011-01-26
EP11152210 2011-01-26
EP11152210.8 2011-01-26
US61/436,207 2011-01-26
PCT/EP2012/050695 WO2012101016A1 (en) 2011-01-26 2012-01-18 Testosterone formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016156246A Division JP2017019819A (ja) 2011-01-26 2016-08-09 テストステロン製剤

Publications (3)

Publication Number Publication Date
JP2014503565A JP2014503565A (ja) 2014-02-13
JP2014503565A5 true JP2014503565A5 (enExample) 2015-03-05
JP6012632B2 JP6012632B2 (ja) 2016-10-25

Family

ID=44146428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013550826A Expired - Fee Related JP6012632B2 (ja) 2011-01-26 2012-01-18 テストステロン製剤
JP2016156246A Withdrawn JP2017019819A (ja) 2011-01-26 2016-08-09 テストステロン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016156246A Withdrawn JP2017019819A (ja) 2011-01-26 2016-08-09 テストステロン製剤

Country Status (28)

Country Link
US (2) US8895053B2 (enExample)
EP (2) EP3072505B1 (enExample)
JP (2) JP6012632B2 (enExample)
KR (1) KR101877476B1 (enExample)
CN (1) CN103327962B (enExample)
AR (1) AR085090A1 (enExample)
AU (1) AU2012210691B2 (enExample)
BR (1) BR112013018951B1 (enExample)
CA (1) CA2824941A1 (enExample)
DK (2) DK3072505T3 (enExample)
ES (2) ES2586122T3 (enExample)
HR (2) HRP20160887T1 (enExample)
HU (3) HUE044327T2 (enExample)
IL (1) IL227454A (enExample)
JO (1) JO3755B1 (enExample)
LT (2) LT3072505T (enExample)
MX (1) MX340259B (enExample)
NO (1) NO2018034I1 (enExample)
PL (2) PL2667851T3 (enExample)
PT (2) PT2667851T (enExample)
RS (2) RS59012B1 (enExample)
RU (1) RU2613891C2 (enExample)
SA (1) SA112330224B1 (enExample)
SI (2) SI3072505T1 (enExample)
TR (1) TR201909271T4 (enExample)
TW (1) TWI564029B (enExample)
WO (1) WO2012101016A1 (enExample)
ZA (1) ZA201305665B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2010125468A1 (en) * 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013178788A2 (en) 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
JP6444956B2 (ja) * 2015-09-30 2018-12-26 富士フイルム株式会社 経皮吸収用組成物
JP7220473B2 (ja) * 2017-10-30 2023-02-10 帝國製薬株式会社 経皮投与製剤
WO2019140087A1 (en) 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
WO2020010205A1 (en) 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
CN109700764B (zh) * 2019-02-20 2021-07-06 广东食品药品职业学院 双氢睾酮原位凝胶喷雾剂及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
JP2719233B2 (ja) 1991-04-25 1998-02-25 デゲンギ，ロマノ 黄体形成ホルモン放出ホルモン拮抗ペプチド
ES2159516T5 (es) 1992-02-12 2005-05-01 Daikyo Gomu Seiko Ltd. Un instrumento medico.
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
AU2004283431B2 (en) * 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CA2646667C (en) * 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
WO2008116825A2 (en) * 2007-03-23 2008-10-02 Unimed Pharmaceuticals, Llc Compositions and method for treating pediatric hypogonadism
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
EP2257324B1 (en) 2008-02-11 2016-07-27 Safety Syringes, Inc. Syringe with safety needle guard and clip to prevent release of guard during reconstitution process
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2010125468A1 (en) 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2012024361A1 (en) * 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
ES2655172T3 (es) 2011-07-15 2018-02-19 Ferring B.V. Procedimiento para preparación temporal de una colonoscopia en la que se administra una composición de picosulfato

Similar Documents

Publication Publication Date Title
JP2014503565A5 (enExample)
AU2012210691B2 (en) Testosterone formulations
CA2646667C (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application
JP2011529038A5 (enExample)
JP2015522049A5 (enExample)
US20050089495A1 (en) Transdermal transport of compounds
WO2010057117A3 (en) Topical transdermal drug delivery compositions
HK1227768A (en) Testosterone formulations
HK1227768A1 (en) Testosterone formulations
NZ613029B (en) Testosterone formulations
HK1192719B (en) Testosterone formulations